IKT Stock Earnings Estimates Increased by HC Wainwright

Inhibikase Therapeutics, Inc. (NASDAQ:IKT – Free Report) – Equities research analysts at HC Wainwright upped their Q1 2027 earnings per share estimates for Inhibikase Therapeutics in a report released on Thursday, November 12th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.12) for the quarter, up from their prior estimate of ($0.13). HC Wainwright currently has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Inhibikase Therapeutics’ current full-year earnings is ($0.42) per share. HC Wainwright also issued estimates for Inhibikase Therapeutics’ Q2 2027 earnings at ($0.11) EPS, Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at ($0.09) EPS and FY2027 earnings at ($0.42) EPS.

Several other analysts also recently weighed in on IKT. Chardan Capital restated a “neutral” rating and set a $1.50 price objective on shares of Inhibikase Therapeutics in a research report on Thursday, November 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Inhibikase Therapeutics in a report on Thursday, October 15th. Finally, Wall Street Zen upgraded Inhibikase Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday. Three equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Inhibikase Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $4.75.

View Our Latest Stock Report on Inhibikase Therapeutics

Inhibikase Therapeutics Trading Down 4.8%

Shares of IKT opened at $1.38 on Monday. Inhibikase Therapeutics has a 52-week low of $1.37 and a 52-week high of $2.61. The business’s fifty day moving average is $1.85 and its 200-day moving average is $1.93.

Inhibikase Therapeutics (NASDAQ:IKT – Get Free Report) last announced its quarterly earnings data on Tuesday, November 10th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.01.

Institutional Investors Weigh In On Inhibikase Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. RA Capital Management L.P. bought a new position in Inhibikase Therapeutics during the third quarter worth $14,323,000. Goldman Sachs Group Inc. grew its holdings in Inhibikase Therapeutics by 96.4% in the third quarter. Goldman Sachs Group Inc. now owns 98,534 shares of the company’s stock worth $202,000 after purchasing an additional 48,364 shares during the period. Soleus Capital Management L.P. increased its stake in Inhibikase Therapeutics by 3.2% in the third quarter. Soleus Capital Management L.P. now owns 11,225,000 shares of the company’s stock valued at $23,067,000 after purchasing an additional 350,000 shares in the last quarter. Alps Advisors Inc. increased its stake in Inhibikase Therapeutics by 37.0% in the third quarter. Alps Advisors Inc. now owns 183,550 shares of the company’s stock valued at $377,000 after purchasing an additional 49,548 shares in the last quarter. Finally, Abel Hall LLC raised its holdings in shares of Inhibikase Therapeutics by 15.0% during the third quarter. Abel Hall LLC now owns 53,311 shares of the company’s stock valued at $110,000 after purchasing an additional 6,959 shares during the period. Institutional investors own 3.81% of the company’s stock.

About Inhibikase Therapeutics

(Get Free Report)

Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for Parkinson’s disease and other neurodegenerative disorders. The company’s research centers on small-molecule inhibitors of Abelson tyrosine kinase, or c-Abl, a protein it is investigating for its role in neurodegeneration. Its pipeline has included IKT-148009, an oral c-Abl inhibitor being developed for Parkinson’s disease. Inhibikase is based in Atlanta, Georgia, and conducts research and development in the pharmaceutical biotechnology sector.

Featured Articles

Earnings History and Estimates for Inhibikase Therapeutics (NASDAQ:IKT)

Receive News & Ratings for Inhibikase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibikase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.